IRF8 and diffuse large B-cell lymphoma: Together with the earlier evidence of oncogenic aberrations targeting its locus (15–17), we propose that IRF8’s role in DLBCL is uniquely multilayered and that both its loss and gain of function may be lymphomagenic.